---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-156127"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:09:34.117486+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics appoints new CFO, additional execs to accelerate vopimetostat development

## Summary
- Daniella Beckman departs as CFO effective April 15; Matthew Gall named successor.
- Matthew Gall receives $540K base salary, 40% target bonus, 240K option shares, 40K RSUs.
- Jessica Newcomb appointed principal accounting officer; Yen-Ching Chua named Chief Development Operations Officer.
- Janice Kapty named SVP Corporate Strategy and Project Leadership; company focuses on vopimetostat for pancreatic cancer.
- Tango plans to present key clinical data in 2026, including combination trial with Revolution Medicines' RAS(ON) inhibitors.

## SEC filing metadata
- accession: 0001193125-26-156127
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312526156127/0001193125-26-156127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312526156127/d144586d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-156127
- JSON: https://secwatch.observer/filing/0001193125-26-156127.json
- Plain text: https://secwatch.observer/filing/0001193125-26-156127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.